Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2-breast cancer

被引：0
|
作者：
Bilani, Nadeem
Yaghi, Marita
Saravia, Diana
Jabbal, Iktej
Zerdan, Maroun Bou
Elson, Leah
Hong, Liang
Nahleh, Zeina
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-08-33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-08-33
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparison of the cost-effectiveness of multigene assays for HR+/HER2-nodenegative early-stage breast cancer in the US
    Berdunov, Vladislav
    Carter, Gebra Cuyun
    Russell, Christy
    Campbell, Sara
    Racz, Jennifer
    Abdou, Yara
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [23] Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2-breast cancer in the US
    Gouldson, Mark
    Berdunov, Vlad
    Le, Quang Anh
    Millen, Steve
    Racz, Jennifer M.
    Arrick, Bradley A.
    Hartzfeld, Deborah
    Thakkar, Snehal Govind
    Heald, Brandie
    Russell, Christy A.
    Eymere, Sebastien
    Moyon, Camille
    Simmons, Harriet
    Carter, Gebra Cuyun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Therapeutic evolution in HR+/HER2-breast cancer: from targeted therapy to endocrine therapy
    Cao, Lu-Qi
    Sun, Haidong
    Xie, Yuhao
    Patel, Harsh
    Bo, Letao
    Lin, Hanli
    Chen, Zhe-Sheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Hiding in plain sight: A heterogeneous response in a patient with metastatic HR+/HER2-breast cancer
    Priedigkeit, Nolan
    Brock, Jane
    Cunningham, Olivia
    Skeffington, Molly
    Hughes, Melissa
    Lin, Nancy
    Lester, Susan
    Parsons, Heather
    CANCER RESEARCH, 2024, 84 (09)
  • [26] The transcription factor CBFB mutations indicate an improved survival in HR+/HER2-breast cancer
    Guo, Liping
    Chen, Bo
    Zhang, Guochun
    Wang, Yulei
    Cao, Li
    Ren, Chongyang
    Wen, Lingzhu
    Lin, Jiali
    Wei, Guangnan
    Liao, Ning
    GENE, 2020, 759
  • [27] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Cancer precision medicine and multi-gene panel testing (MGPT) overview
    Hirasawa, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1283 - S1283
  • [29] Multimodal integration using a machine learning approach facilitates risk stratification in HR+/HER2-breast cancer
    Zhang, Hang
    Yang, Fan
    Xu, Ying
    Zhao, Shen
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    Xiao, Yi
    CELL REPORTS MEDICINE, 2025, 6 (02)
  • [30] Integrated analysis of cell cycle-related genes in HR+/HER2-breast cancer
    Lai, Jianguo
    Chen, Bo
    Li, Yingzi
    Lin, Xiaoyi
    Li, Min
    Liu, Jing
    Liao, Ning
    BREAST CANCER, 2022, 29 (01) : 121 - 130
12345